• According to Transparency Market Research’s latest report on the global human vaccine market for the historical period 2017–2018 and forecast period 2019–2027, extremely low risk of serious and fatal side effects, education and awareness through various governmental and non-profit organizations, growing preference for outsourcing of vaccine manufacturing are projected to drive the global human vaccine market during the forecast period
  • According to the report, the global human vaccine market was valued at US$ 37.8 Bn in 2018 and is anticipated to expand at a CAGR of 8.7% from 2019 to 2027

Request a sample to get extensive insights into the Human Vaccines Market

Extremely Low Risk of Serious and Fatal Side Effects: Key Drivers

  • Like other drugs, vaccines are also associated with certain side effects. However, most of the times, side effects from vaccination are mild and moderate such as soreness, swelling, or redness at the site of injection and fever, rash, and achiness.
  • The risk of serious and fatal side effects with vaccination is extremely low. For instance, serious allergic reaction with Anthrax vaccine is less than once for every 100,000 doses. A number of health care organizations including the CDC, the FDA, the American Medical Association (AMA), and the American Academy of Pediatrics (AAP) also recommend that vaccines are safe.
  • Extremely low risk of serious and fatal side effects associated with vaccines drive the market for vaccines during the forecast period.

Education and Awareness through Various Governmental and Non-Profit Organizations Boost Market Growth

  • The vaccine market is also growing due to increasing awareness and education about the benefits associated with vaccination programs. Every year in the U.S., August is celebrated as the National Immunization Awareness Month.
  • During this month, families, friends, and colleagues are reminded to stay up-to-date on vaccine shots. People also share strategies to increase immunization rates among their communities.
  • The National Association of School Nurses, a non-profit specialty nursing organization, along with Sanofi Pasteur is creating awareness to help prevent children and teens from getting infected by meningococcal disease, through a public health initiative ‘Voices of Meningitis’. Increasing awareness among people as a result of the aforementioned initiatives is likely to contribute to market growth during the forecast period from 2019 to 2027

Strict Regulatory Pathway and High Cost Associated With New Vaccine Discovery and Development to Hamper Market

  • Regulatory requirements for developing a new vaccine are quite challenging, and a company engaged in the discovery and development of a new vaccine can take up to 12 years to 15 years to commercialize it.
  • The average cost to discover and develop a new vaccine is estimated to be US$ 1,000 Mn to US$ 2,000 Mn.
  • Therefore, stringent regulatory approval process and high cost associated with new vaccine discovery and development have been identified as major restraints of the market during the forecast period from 2019 to 2027.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Global Human vaccine Market: Competitive Landscape

  • This report profiles major players in the global human vaccine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global human vaccine market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global human vaccine market are
    • AstraZeneca plc
    • Bavarian Nordic
    • Bharat Biotech
    • CSL Limited, Emergent BioSolutions, Inc.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co, Inc.
    • Mymetics
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Shenzhen Kangtai Biological Products Co., Ltd.
    • Takeda Pharmaceutical Company Limited.
    • among others

Stuck in a neck-to-neck competition with other brands? Request a custom report on Human Vaccines Market

Global Human vaccine Market: Key Developments

Key players in the global human vaccine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global human vaccine market. A few expansion strategies adopted by players operating in the global human vaccine market are:

  • In September 2016, Mymetics collaborated with the Texas Biomedical Research Institute. The two organizations would work together to develop a HIV vaccine for Mymetics.
  • In May 2016, CSL Limited received the U.S. FDA approval for FLUCELVAX QUADRIVALENT influenza vaccine primarily used for pediatrics

The report on the global human vaccine market discussed individual strategies, followed by company profiles of manufacturers of human vaccine. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global human vaccine market.

Global Human Vaccine Market – Segmentation

Vaccine Type

  • Conjugate
  • Recombinant
  • Inactivated
  • Combination
  • Attenuated
  • Others

Product Type

  • Pneumococcal
  • Influenza
  • Hepatitis
  • HPV
  • Meningococcal
  • Rotavirus
  • Measles and Rubella
  • Typhoid
  • Combination
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Drugstores
  • Others

Age Group

  • Pediatrics
  • Adolescents
  • Adults
  • Geriatrics

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

Human vaccine market to reach the valuation of US$ 81,346.4 Mn by 2027

Human vaccine market is anticipated to expand at a CAGR of 8.7% from 2019 to 2027

Human vaccine market is driven by extremely low risk of serious and fatal side effects associated with vaccines

Key players operating in the human vaccines market include Sanofi S. A., Pfizer, Inc., Novartis AG, Mymetics, Merck & Co, Inc., Johnson & Johnson, GlaxoSmithKline Plc., Bharat Biotech, and Bavarian Nordic.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Human Vaccine Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Human Vaccine Market Analysis and Forecasts, 2018–2030

5. Key Insights

    5.1. Product Overview

    5.2. Key Industry Developments

    5.3. Emerging Trends in Human Vaccines Market

6. Global Human Vaccine Market Analysis and Forecasts, By Vaccine

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value  Forecast By Vaccine, 2018–2030

        6.3.1. Conjugate

        6.3.2. Recombinant

        6.3.3. Inactivated

        6.3.4. Combination

        6.3.5. Attenuated

        6.3.6. Others

    6.4. Market Attractiveness By Vaccine

7. Global Human Vaccine Market Analysis and Forecasts, By Product

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value  Forecast By Product, 2018–2030

        7.3.1. Pneumococcal

        7.3.2. Influenza

        7.3.3. Hepatitis

        7.3.4. HPV

        7.3.5. Meningococcal

        7.3.6. Rotavirus

        7.3.7. Measles and Rubella

        7.3.8. Typhoid

        7.3.9. Combination

        7.3.10. Others

    7.4. Market Attractiveness By Product

8. Global Human Vaccine Market Analysis and Forecasts, By Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value  Forecast By Distribution Channel, 2018–2030

        8.3.1. Hospital Pharmacies

        8.3.2. Drugstores

        8.3.3. Others

    8.4. Market Attractiveness By Distribution Channel

9. Global Human Vaccine Market Analysis and Forecasts, By Age Group

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value  Forecast By Age Group, 2018–2030

        9.3.1. Pediatrics

        9.3.2. Adolescents

        9.3.3. Adults

        9.3.4. Geriatrics

    9.4. Market Attractiveness By Age Group

10. Global Human Vaccine Market Analysis and Forecasts, By Region

    10.1. Key Findings

    10.2. Market Value  Forecast By Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness By Region

11. North America Human Vaccine Market Analysis and Forecast

    11.1. Introduction

    11.2. Market Value  Forecast By Vaccine, 2018–2030

        11.2.1. Conjugate

        11.2.2. Recombinant

        11.2.3. Inactivated

        11.2.4. Combination

        11.2.5. Attenuated

        11.2.6. Others

    11.3. Market Value  Forecast By Product, 2018–2030

        11.3.1. Pneumococcal

        11.3.2. Influenza

        11.3.3. Hepatitis

        11.3.4. HPV

        11.3.5. Meningococcal

        11.3.6. Rotavirus

        11.3.7. Measles and Rubella

        11.3.8. Typhoid

        11.3.9. Combination

        11.3.10. Others

    11.4. Market Value  Forecast By Distribution Channel, 2018–2030

        11.4.1. Hospital Pharmacies

        11.4.2. Drugstores

        11.4.3. Others

    11.5. Market Value  Forecast By Age Group, 2018–2030

        11.5.1. Pediatrics

        11.5.2. Adolescents

        11.5.3. Adults

        11.5.4. Geriatrics

    11.6. Market Value  Forecast By Country, 2018–2030

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Vaccine

        11.7.2. By Product

        11.7.3. By Distribution Channel

        11.7.4. By Age Group

        11.7.5. By Country

12. Europe Human Vaccine Market Analysis and Forecast

    12.1. Introduction

    12.2. Market Value  Forecast By Vaccine, 2018–2030

        12.2.1. Conjugate

        12.2.2. Recombinant

        12.2.3. Inactivated

        12.2.4. Combination

        12.2.5. Attenuated

        12.2.6. Others

    12.3. Market Value  Forecast By Product, 2018–2030

        12.3.1. Pneumococcal

        12.3.2. Influenza

        12.3.3. Hepatitis

        12.3.4. HPV

        12.3.5. Meningococcal

        12.3.6. Rotavirus

        12.3.7. Measles and Rubella

        12.3.8. Typhoid

        12.3.9. Combination

        12.3.10. Others

    12.4. Market Value  Forecast By Distribution Channel, 2018–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Drugstores

        12.4.3. Others

    12.5. Market Value  Forecast By Age Group, 2018–2030

        12.5.1. Pediatrics

        12.5.2. Adolescents

        12.5.3. Adults

        12.5.4. Geriatrics

    12.6. Market Value  Forecast By Country, 2018–2030

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Vaccine

        12.7.2. By Product

        12.7.3. By Distribution Channel

        12.7.4. By Age Group

        12.7.5. By Country

13. Asia Pacific Human Vaccine Market Analysis and Forecast

    13.1. Introduction

    13.2. Market Value  Forecast By Vaccine, 2018–2030

        13.2.1. Conjugate

        13.2.2. Recombinant

        13.2.3. Inactivated

        13.2.4. Combination

        13.2.5. Attenuated

        13.2.6. Others

    13.3. Market Value  Forecast By Product, 2018–2030

        13.3.1. Pneumococcal

        13.3.2. Influenza

        13.3.3. Hepatitis

        13.3.4. HPV

        13.3.5. Meningococcal

        13.3.6. Rotavirus

        13.3.7. Measles and Rubella

        13.3.8. Typhoid

        13.3.9. Combination

        13.3.10. Others

    13.4. Market Value  Forecast By Distribution Channel, 2018–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Drugstores

        13.4.3. Others

    13.5. Market Value  Forecast By Age Group, 2018–2030

        13.5.1. Pediatrics

        13.5.2. Adolescents

        13.5.3. Adults

        13.5.4. Geriatrics

    13.6. Market Value  Forecast By Country, 2018–2030

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Vaccine

        13.7.2. By Product

        13.7.3. By Distribution Channel

        13.7.4. By Age Group

        13.7.5. By Country

14. Latin America Human Vaccine Market Analysis and Forecast

    14.1. Introduction

    14.2. Market Value  Forecast By Vaccine, 2018–2030

        14.2.1. Conjugate

        14.2.2. Recombinant

        14.2.3. Inactivated

        14.2.4. Combination

        14.2.5. Attenuated

        14.2.6. Others

    14.3. Market Value  Forecast By Product, 2018–2030

        14.3.1. Pneumococcal

        14.3.2. Influenza

        14.3.3. Hepatitis

        14.3.4. HPV

        14.3.5. Meningococcal

        14.3.6. Rotavirus

        14.3.7. Measles and Rubella

        14.3.8. Typhoid

        14.3.9. Combination

        14.3.10. Others

    14.4. Market Value  Forecast By Distribution Channel, 2018–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Drugstores

        14.4.3. Others

    14.5. Market Value  Forecast By Age Group, 2018–2030

        14.5.1. Pediatrics

        14.5.2. Adolescents

        14.5.3. Adults

        14.5.4. Geriatrics

    14.6. Market Value  Forecast By Country, 2018–2030

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Vaccine

        14.7.2. By Product

        14.7.3. By Distribution Channel

        14.7.4. By Age Group

        14.7.5. By Country

15. Middle East & Africa Human Vaccine Market Analysis and Forecast

    15.1. Introduction

    15.2. Market Value  Forecast By Vaccine, 2018–2030

        15.2.1. Conjugate

        15.2.2. Recombinant

        15.2.3. Inactivated

        15.2.4. Combination

        15.2.5. Attenuated

        15.2.6. Others

    15.3. Market Value  Forecast By Product, 2018–2030

        15.3.1. Pneumococcal

        15.3.2. Influenza

        15.3.3. Hepatitis

        15.3.4. HPV

        15.3.5. Meningococcal

        15.3.6. Rotavirus

        15.3.7. Measles and Rubella

        15.3.8. Typhoid

        15.3.9. Combination

        15.3.10. Others

    15.4. Market Value  Forecast By Distribution Channel, 2018–2030

        15.4.1. Hospital Pharmacies

        15.4.2. Drugstores

        15.4.3. Others

    15.5. Market Value  Forecast By Age Group, 2018–2030

        15.5.1. Pediatrics

        15.5.2. Adolescents

        15.5.3. Adults

        15.5.4. Geriatrics

    15.6. Market Value  Forecast By Country, 2018–2030

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Vaccine

        15.7.2. By Product

        15.7.3. By Distribution Channel

        15.7.4. By Age Group

        15.7.5. By Country

16. Competition Landscape

    16.1. Market Share Analysis By Company (2019)

    16.2. Company Profiles

        16.2.1. AstraZeneca plc

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Growth Strategies

            16.2.1.3. SWOT Analysis

        16.2.2. Bavarian Nordic

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Growth Strategies

            16.2.2.3. SWOT Analysis

        16.2.3. Bharat Biotech

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Growth Strategies

            16.2.3.3. SWOT Analysis

        16.2.4. CSL Limited

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Growth Strategies

            16.2.4.3. SWOT Analysis

        16.2.5. Emergent BioSolutions, Inc.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Growth Strategies

            16.2.5.3. SWOT Analysis

        16.2.6. GlaxoSmithKline plc.

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Growth Strategies

            16.2.6.3. SWOT Analysis

        16.2.7. Johnson & Johnson

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Growth Strategies

            16.2.7.3. SWOT Analysis

        16.2.8. Merck & Co, Inc.

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Growth Strategies

            16.2.8.3. SWOT Analysis

        16.2.9. Mymetics

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Growth Strategies

            16.2.9.3. SWOT Analysis

        16.2.10. Novartis AG

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Growth Strategies

            16.2.10.3. SWOT Analysis

        16.2.11. Pfizer, Inc.

            16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.11.2. Growth Strategies

            16.2.11.3. SWOT Analysis

        16.2.12. Sanofi S.A.

            16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.12.2. Growth Strategies

            16.2.12.3. SWOT Analysis

        16.2.13. Shenzhen Kangtai Biological Products Co., Ltd.

            16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.13.2. Growth Strategies

            16.2.13.3. SWOT Analysis

        16.2.14. Takeda Pharmaceutical Company Limited

            16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.14.2. Growth Strategies

            16.2.14.3. SWOT Analysis

List of Tables

Table 01 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

Table 02 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 03 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

Table 04 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

Table 05 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2019–2027

Table 06 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 07 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 08 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

Table 09 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

Table 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

Table 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2019–2027

Table 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

Table 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

Table 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

Table 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

Table 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

Table 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

Table 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

Table 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

Table 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

Table 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

Table 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

List of Figure

Figure 01 Global Human Vaccines Market Value Share Analysis, by Vaccine Type, 2018 and 2027

Figure 02 Global Conjugate Market Revenue (US$ Mn), 2017–2027

Figure 03 Global Recombinant Market Revenue (US$ Mn), 2017–2027

Figure 04 Global Inactivated Market Revenue (US$ Mn), 2017–2027

Figure 05 Global Combination Market Revenue (US$ Mn), 2017–2027

Figure 06 Global Attenuated Market Revenue (US$ Mn), 2017–2027

Figure 07 Global Others Market Revenue (US$ Mn), 2017–2027

Figure 08 Human Vaccines Market Attractiveness Analysis, by Vaccine Type, 2018

Figure 09 Global Human Vaccines Market Value Share Analysis, by Product, 2018 and 2027

Figure 10 Global Pneumococcal Market Revenue (US$ Mn), 2017–2027

Figure 11 Global Influenza Market Revenue (US$ Mn), 2017–2027

Figure 12 Global Hepatitis Market Revenue (US$ Mn), 2017–2027

Figure 13 Global HPV Market Revenue (US$ Mn), 2017–2027

Figure 14 Global Meningococcal Market Revenue (US$ Mn), 2017–2027

Figure 15 Global Rotavirus Market Revenue (US$ Mn), 2017–2027

Figure 16 Global Measles and Rubella Market Revenue (US$ Mn), 2017–2027

Figure 17 Global Typhoid Market Revenue (US$ Mn), 2017–2027

Figure 18 Global Combination Market Revenue (US$ Mn), 2017–2027

Figure 19 Global Others Market Revenue (US$ Mn), 2017–2027

Figure 20 Human Vaccines Market Attractiveness Analysis, by Product, 2018

Figure 21 Global Human Vaccines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 22 Global Hospital Pharmacies Market Revenue (US$ Mn), 2017–2027

Figure 23 Global Drugstores Market Revenue (US$ Mn), 2017–2027

Figure 24 Global others Market Revenue (US$ Mn), 2017–2027

Figure 25 Human Vaccines Market Attractiveness Analysis, by Distribution Channel, 2018

Figure 26 Global Human Vaccines Market Value Share Analysis, by Age Group, 2018 and 2027

Figure 27 Global Pediatrics Market Revenue (US$ Mn), 2017–2027

Figure 28 Global Adolescents Market Revenue (US$ Mn), 2017–2027

Figure 29 Global Adults Market Revenue (US$ Mn), 2017–2027

Figure 30 Global Geriatrics Market Revenue (US$ Mn), 2017–2027

Figure 31 Human Vaccines Market Attractiveness Analysis, by Age Group, 2018

Figure 32 North America Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 33 Europe Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 34 APAC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 35 Latin America Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 36 MEA Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 37 Global Human Vaccines Market Attractiveness Analysis, by Region

Figure 38 China Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 39 Japan Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 40 ASEAN Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 41 Rest of APAC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 42 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Country

Figure 43 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Product

Figure 44 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Vaccine Type

Figure 45 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Age Group

Figure 46 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Distribution Channel

Figure 47 U.S. Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 48 Canada Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 49 North America Human Vaccines Market Attractiveness Analysis, by Country

Figure 50 North America Human Vaccines Market Attractiveness Analysis, by Product

Figure 51 North America Human Vaccines Market Attractiveness Analysis, by Vaccine Type

Figure 52 North America Human Vaccines Market Attractiveness Analysis, by Age Group

Figure 53 North America Human Vaccines Market Attractiveness Analysis, by Distribution Channel

Figure 54 Germany Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 55 France Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 56 U.K. Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 57 Italy Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 58 Spain Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 59 Rest of Europe Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 60 Europe Human Vaccines Market Attractiveness Analysis, by Country

Figure 61 Europe Human Vaccines Market Attractiveness Analysis, by Product

Figure 62 Europe Human Vaccines Market Attractiveness Analysis, by Vaccine Type

Figure 63 Europe Human Vaccines Market Attractiveness Analysis, by Age Group

Figure 64 Europe Human Vaccines Market Attractiveness Analysis, by Distribution Channel

Figure 65 Brazil Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 66 Mexico Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 67 Rest of LATAM Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 68 Latin America Human Vaccines Market Attractiveness Analysis, by Country

Figure 69 Latin America Human Vaccines Market Attractiveness Analysis, by Product

Figure 70 Latin America Human Vaccines Market Attractiveness Analysis, by Vaccine Type

Figure 71 Latin America Human Vaccines Market Attractiveness Analysis, by Age Group

Figure 72 Latin America Human Vaccines Market Attractiveness Analysis, by Distribution Channel

Figure 73 GCC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 74 South Africa Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 75 Rest of MEA Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

Figure 76 MEA Human Vaccines Market Attractiveness Analysis, by Country

Figure 77 MEA Human Vaccines Market Attractiveness Analysis, by Product

Figure 78 MEA Human Vaccines Market Attractiveness Analysis, by Vaccine Type

Figure 79 MEA Human Vaccines Market Attractiveness Analysis, by Age Group

Figure 80 MEA Human Vaccines Market Attractiveness Analysis, by Distribution Channel

Figure 81 Human Vaccine Market Share Analysis, by Company (2018)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Human Vaccines Market